Combined treatment of hepatocellular carcinoma with partial splenic embolization and transcatheter hepatic arterial chemoembolization

Table 1 Demographic, clinical, histological and laboratory characteristics of patients n (%)

Characteristics	Group A, n	Group B	P-value
Patients	26	24
Sex
Male	19 (73)	18 (75)	0.8771
Female	7 (27)	6 (25)
Age (yr)	44.1 ± 12.1	45.0 ± 9.0	0 .7602
Child-Pugh grade
A	2 (8)	2 (8)
B	20 (77)	19 (79)	0.8061
C	4 (15)	3 (13)
Pathology type
Mass type	14 (54)	14 (58)	0.8341
Node type	10 (38)	8 (33)
Diffusion type	2 (8)	2 (8)
Tumor diameter (cm)
Peripheral blood cell counts	4.64 ± 2.34	4.44 ± 2.58	0.7802
WBC (× 109)	2.45 ± 0.41	2.40 ± 0.51	0.7342
PLT (× 109)	45.95 ± 9.49	45.02 ± 8.96	0.7232
RBC (× 1012)	3.02 ± 0.49	3.07 ± 0.51	0.7502

¹Data are determined with the χ² test;

²Data are determined with the t-test.

Table 2 Follow-up results of WBC counts (× 10⁹/L)

Time	Group A		Group B		P-value2
	mean ± SD	P-value1	mean ± SD	P-value1
Pre-treatment	2.45 ± 0.41		2.40 ± 0.51		0.734
Post-treatment
1 wk	7.26 ± 0.96	< 0.001	1.77 ± 0.38	< 0.001	< 0.001
2 wk	6.42 ± 1.02	< 0.001	1.68 ± 0.39	< 0.001	< 0.001
1 mo	6.31 ± 0.83	< 0.001	1.72 ± 0.65	< 0.001	< 0.001
2 mo	6.03 ± 0.93	< 0.001	1.91 ± 0.73	0.0032	< 0.001
3 mo	5.36 ± 0.64	< 0.001	2.02 ± 0.48	0.013	< 0.001

¹Comparison of WBC counts before and after treatment at different time points within each group;

²Comparison of WBC counts between the two groups at different time points determined with t-test.

Table 3 Follow-up results of PLT counts (× 10⁹/L)

Time	Group A		Group B		P-value2
	mean ± SD	P-value1	mean ± SD	P-value1
Pre-treatment	45.95 ± 9.49		45.02 ± 8.96		0.723
Post-treatment
1 wk	169.21 ± 26.55	< 0.001	28.56 ± 5.11	< 0.001	< 0.001
2 wk	136.50 ± 13.12	< 0.001	26.62 ± 7.31	< 0.001	< 0.001
1 mo	133.46 ± 16.21	< 0.001	27.46 ± 6.29	< 0.001	< 0.001
2 mo	125.73 ± 18.35	< 0.001	31.06 ± 6.70	< 0.001	< 0.001
3 mo	119.86 ± 12.43	< 0.001	33.15 ± 6.91	< 0.001	< 0.001

¹Comparison of PLT counts before and after treatment at different time points within each group;

²Comparison of PLT counts between the two groups at different time points determined with t-test.

Table 4 Follow-up results of RBC counts (× 10¹²/L)

Time	Group A		Group B		P-value2
	mean ± SD	P-value1	mean ± SD	P-value1
Pre-treatment	3.02 ± 0.49		3.07 ± 0.51		0.75
Post-treatment
1 wk	2.84 ± 0.72	0.297	2.93 ± 0.56	0.375	0.639
2 wk	2.88 ± 0.54	0.325	2.97 ± 0.68	0.583	0.606
1 mo	2.81 ± 0.36	0.073	2.93 ± 0.71	0.442	0.430
2 mo	2.92 ± 0.42	0.418	2.85 ± 0.62	0.185	0.623
3 mo	3.04 ± 0.50	0.924	2.97 ± 0.47	0.439	0.644

¹Comparison of RBC counts before and after treatment at different time points within each group;

²Comparison of RBC counts between the two groups at different time points determined with t-test.

Table 5 Complications observed in 50 patients 2 wk after treatment n (%)

Complications	Group A	Group B	P-value
Abdominal pain	20 (76.9)	18 (75.0)	0.8741
Fever	22 (84.6)	20 (83.3)	0.9031
Mild nausea and vomiting	5 (19.2)	6 (25.0)	0.6231
Large amount of pleural effusion or ascites	1 (3.9)	6 (29.2)	0.0161
Bacterial peritonitis	1 (3.9)	6 (25.0)	0.0331
Variceal bleeding	1 (3.9)	7 (29.2)	0.0161

¹Data are determined with the χ² test.